Forum: Covid-19: WHO recommends Merck’s pill with conditions – ABC Bourse

- Advertisement -

Real time course: 6.489.23 -0.14%

- Advertisement -

“The results of these trials show that molnupiravir reduces the risk of hospitalization (43 fewer admissions per 1000 high-risk patients) and the time to resolution of symptoms (3.4 days less on average). 6 fewer deaths).” Measures of language and data tend to show that we are far from a miracle cure…

- Advertisement -

Capsules of American Merck’s anti-Kovid pill molnupiravir (Merck & Co, Inc./AFP/Archives/Handout)

- Advertisement -

The World Health Organization (WHO) on Wednesday recommended the anti-Covid pill of American Merck (MSD) for patients with Covid 19 who still have a mild course but are at high risk of hospitalization, especially for the elderly.

This treatment, called molnupiravir, is an antiviral that must be administered immediately after the onset of symptoms and must be taken for five days to prevent the virus from multiplying.

It is recommended for “non-severe Covid-19 patients who are most at risk for hospitalization,” an international expert panel of WHO international experts told the British Medical Journal on Wednesday (BMJ).

These patients at risk of hospitalization are unvaccinated, elderly, immunocompromised, or people with chronic diseases.

The WHO panel, on the other hand, believes that “young and healthy patients, including children, pregnant and lactating women,” should not receive treatment.

This recommendation is based on new data from six randomized controlled trials involving 4,796 patients, the largest dataset on this drug to date, and details WHO in a press release.

The results of these studies show that molnupiravir reduces the risk of hospitalization (43 fewer admissions per 1000 high-risk patients) and the time to resolution of symptoms (average 3.4 days less).

Less precisely, they highlight a weak effect on mortality (6 fewer deaths per 1,000 patients).

The WHO panel recognizes that the cost and availability issues of molnupiravir can complicate access and increase health inequalities in low- and middle-income countries.

Experts also recommend a treatment combining Regeneron’s monoclonal antibodies (casirivimab and indevimab) only for people who are confirmed not to be infected with the Omicron variant. Indeed, these antibodies have proven to be ineffective against the variant.

Molnupiravir is the only anti-Covid pill from American Pfizer that contains Paxlovid. But Merck’s treatment is more of a concern than the latter when it comes to side effects.

For example, the United States Medicines Agency has not allowed this for children under the age of 18 as it may affect the development of bone and cartilage.

© 2022 AFP

Source From: Google News

- Advertisement -

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

2,061FansLike
0FollowersFollow
0SubscribersSubscribe

Latest Articles